NCT05181891 (PERRAS) is a Phase 2 clinical trial of Contingency Management in Alcohol Use Disorder (AUD), sponsored by Washington State University.

Who is sponsoring NCT05181891?

NCT05181891 is sponsored by Washington State University.

What drugs are being tested in NCT05181891?

Interventions in NCT05181891: Contingency Management, Non-contingent control.

What condition does NCT05181891 study?

NCT05181891 studies Alcohol Use Disorder (AUD), Nicotine Use Disorder.

Is NCT05181891 still recruiting?

NCT05181891 is currently recruiting now. Last updated 25 June 2024.

Last reviewed 2024-06-25 · How we verify

NCT05181891: PERRAS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pharmaceutically-Enhanced Reinforcement for Reduced Alcohol and Smoking

Recruiting now Phase 2 Last updated 25 June 2024

What this trial tests

Phase 2 trial testing Contingency Management in Alcohol Use Disorder (AUD) in 205 participants. Currently enrolling.

Timeline

11 July 2022

Primary endpoint
1 May 2026

1 May 2026

Quick facts

Lead sponsor	Washington State University
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	205
Start date	11 July 2022
Primary completion	1 May 2026
Estimated completion	1 May 2026
Sites	1 location across United States

Drugs / interventions tested

Contingency Management
Non-contingent control

Conditions studied

Alcohol Use Disorder (AUD) — all drugs for Alcohol Use Disorder (AUD) →
Nicotine Use Disorder — all drugs for Nicotine Use Disorder →

Sponsor

Washington State University

Who can join

18 and older, any sex, with Alcohol Use Disorder (AUD) or Nicotine Use Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Using a randomized controlled trial (RCT), the goal of this study is to evaluate the ability of evidence based behavioral treatment (contingency management: CM) to significantly decrease alcohol use and cigarette smoking among treatment-seeking smokers with an alcohol use disorder (AUD) who have initiated pharmacotherapy (varenicline; VC) for smoking cessation.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Incentives for smoking cessation.
Notley C, Gentry S, Livingstone-Banks J, Bauld L, et al · · 2025 · cited 9× · PMID 39799985 · DOI 10.1002/14651858.cd004307.pub7

Verify or expand the search:

Other trials of Contingency Management

Trials testing the same drug.

NCT07281378 — Reducing Co-occurring Substance Use and HIV Risk Among Stimulant-using Men at High Risk for HIV in the United States of · NA · not yet recruiting
NCT07218471 — Cannabis Reduction and Functional Outcomes · NA · recruiting
NCT07226596 — Non-Abstinence Outcomes in Methamphetamine Use Disorder · NA · recruiting
NCT07129902 — Contingency Management to Improve Medication for Opioid Use Disorder Continuation After the Emergency Department · NA · not yet recruiting
NCT06432985 — Smoking Cessation CM for Veterans With or at Risk for Cancer · NA · recruiting

Other recruiting trials for Alcohol Use Disorder (AUD)

Currently open trials in the same condition.

NCT07118618 — Probenecid Administration for Alcohol Craving and Consumption · Phase 2 · recruiting
NCT07040592 — Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 Semaglutide · Phase 2 · recruiting
NCT06949423 — Assessing the Impact of dTMS on Neural Targets Associated With Alcohol Use Disorder · NA · recruiting
NCT06070649 — The Potential Therapeutic Effects of Psychedelic, N, N-dimethyltryptamine (DMT), on Alcohol Use Disorder (AUD) · Phase 1 · recruiting
NCT06335407 — Effect of Sublingual Formulation of Dexmedetomidine Hydrochloride (HCl) (BXCL501) - Outpatient Study · Phase 1 · recruiting

Other Washington State University trials

Trials by the same sponsor.

NCT07088237 — Testing a Music Listening mHealth Intervention for Stress Reduction in Early Recovery (CalmiFy II) · NA · not yet recruiting
NCT07393672 — Effects of Hemp-Derived Cannabinoids on Menopause Symptoms · Phase 2 · recruiting
NCT07171359 — TMS to Improve Recovery Outcomes Among Patients With Opioid Use Disorder (OUD) and Alcohol Use Disorder (AUD) · NA · not yet recruiting
NCT07052318 — Developing a Music Listening mHealth Intervention for Stress Reduction in Early Recovery · recruiting
NCT06804239 — Improving Activity in Adults With Chronic Pain With Online Resources · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05181891 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Washington State University
Last refreshed: 25 June 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05181891.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing